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Abstract
Proteolytic processing of Gag and Gag-Pol polyproteins by the viral protease (PR) is crucial for the production of infectious
HIV-1, and inhibitors of the viral PR are an integral part of current antiretroviral therapy. The process has several layers of
complexity (multiple cleavage sites and substrates; multiple enzyme forms; PR auto-processing), which calls for a systems
level approach to identify key vulnerabilities and optimal treatment strategies. Here we present the first full reaction kinetics
model of proteolytic processing by HIV-1 PR, taking into account all canonical cleavage sites within Gag and Gag-Pol,
intermediate products and enzyme forms, enzyme dimerization, the initial auto-cleavage of full-length Gag-Pol as well as
self-cleavage of PR. The model allows us to identify the rate limiting step of virion maturation and the parameters with the
strongest effect on maturation kinetics. Using the modelling framework, we predict interactions and compensatory
potential between individual cleavage rates and drugs, characterize the time course of the process, explain the steep dose
response curves associated with PR inhibitors and gain new insights into drug action. While the results of the model are
subject to limitations arising from the simplifying assumptions used and from the uncertainties in the parameter estimates,
the developed framework provides an extendable open-access platform to incorporate new data and hypotheses in the
future.
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Introduction
The morphological maturation of human immunodeficiency
virus type 1 (HIV-1) depends on the proteolytic processing of the
Gag and Gag-Pol polyproteins by the virus encoded PR that
occurs concomitant with or shortly after virus release [1]. PR
inhibitors (PIs) that interfere with this process result in the
production of immature, noninfectious virus particles, and
constitute an important drug class in anti-HIV-1 therapy [2,3].
While currently approved drugs act by competitive binding to the
PR active site, thereby affecting all cleavage events, individual
steps of the maturation process are also potential targets for future
drug development [4,5]. The development and therapeutic
application of HIV-1 maturation inhibitors requires a detailed
understanding of the cleavage process, which has multiple layers of
complexity. First, PR itself is embedded in the Gag-Pol
polyprotein, and Gag-Pol auto-processing is required to initiate
the maturation process [6–9]. Liberated PR molecules then
catalyze further cleavage events, which might result in accelerated
PR release by a positive feedback loop. Second, due to its relatively
broad substrate specificity [10], HIV PR targets 11 canonical
cleavage sites in the Gag and Gag-Pol polyproteins (Figure 1),
generating 66 distinct molecular species (substrates, intermediates
and products), and a large number of competing reactions occur
simultaneously within the confined space of the virion. Cleavage at
the individual sites occurs with different rates; a 400-fold difference
in rate between the fastest (SP1-NC) and slowest (CA-SP1)
cleavage site in Gag has been determined in vitro [11]. Third,
several intermediates include an active protease domain, but also
one or more uncleaved cleavage sites: these molecular species have
dual roles as both substrates and enzymes in the reaction network.
The complexity of the reaction system (number of reactions/
reactants) is comparable to that of the cell cycle, which has been
among the most important targets of systems modelling in biology
so far [12].
Understanding and predicting the behaviour of this complex
system requires systems modelling and extensive empirical data to
parameterize the model. Accumulating data on the kinetic
parameters of the cleavage reactions [6–9,13–20] and on the
biology of HIV-1 virion assembly and maturation [21–26] now
allow us to tackle this problem, and we here present the first full
reaction kinetics model of proteolytic processing by HIV-1 PR.
PLOS Computational Biology | www.ploscompbiol.org 1 June 2013 | Volume 9 | Issue 6 | e1003103
We use the model to characterize the general time course of the
process, to identify the parameters with the strongest effect on the
maturation process, to assess interactions between the parameters
and the potential of individual parameters to compensate for drug
effects or changes in other parameters, and to explain the steep
dose response curves associated with PIs [27]. While subject to
inevitable limitations arising from the simplifying assumptions used
and from uncertainty in the parameter estimates, our model results
provide a level of resolution exceeding that of currently available
experimental data. The time course of proteolytic processing has
been characterized quantitatively for purified Gag in vitro [11], but
was determined only qualitatively for Gag-Pol [28], and experi-
ments are typically limited to tracking a small number of
molecular species in simplified in vitro systems. In contrast, the
model presented here tracks all intermediates and products of the
complex reaction system. Furthermore, the model can be used to
predict the effect of quantitatively characterized mutations or
drugs alone or in combination. It can also be applied to predict the
effect of potential perturbations induced by compounds in drug
development. Systems modelling has been used to identify and
characterize synergistic drug interactions that can enhance the
effect of drugs [29,30]. The model presented here opens the
possibility to apply this approach to HIV-1 PR inhibition.
Results
Time course of Gag-Pol processing and virion maturation
We built a full model of PR catalyzed Gag- and Gag-Pol
processing based on mass action Michaelis-Menten reaction
kinetics (Materials and Methods). Based on published data on
the architecture of the immature HIV-1 particle [22], we set initial
concentrations to correspond to 2,280 molecules of Gag (corre-
sponding to 3.619 mM) and 120 molecules of Gag-Pol (corre-
sponding to 0.195 mM) within the confined space of a spherical
virus particle with a radius of 63 nm [22] as the starting point for
our simulations. By parameterizing all cleavage reactions accord-
ing to in vitro empirical estimates (Table 1), our model generated a
detailed predicted time course for the cleavage process (Figure 2;
major intermediates are shown in Figure S1). The timing of virion
maturation (virion maturation time, VMT; dashed red line in all
Figure 1. The scheme of Gag and Gag-Pol processing by HIV-1 PR. Our model includes the 11 canonical cleavage sites at which the PR
cleaves the polyproteins to release the functional enzymes and structural proteins of the virus (indicated by numbers 1–11). A cleavage site within PR
itself that mediates auto-inactivation of proteolytic activity is indicated by a dashed line (12). RT is active as a heterodimer of p51 and p66 (p51 and
p15 still uncleaved). Abbreviations: MA – matrix, CA – capsid, SP1 – spacer peptide 1, NC – nucleocapsid, SP2 – spacer peptide 2, TFP – transframe
peptide, PR – protease, RT – reverse transcriptase, IN – integrase. Boxes representing individual domains are not drawn to scale.
doi:10.1371/journal.pcbi.1003103.g001
Author Summary
Human Immunodeficiency Virus (HIV) produces its struc-
tural proteins and key enzymes in the form of polypro-
teins, from which the individual proteins need to be
released in a complex and tightly regulated series of
cleavage reactions to give rise to a morphologically
mature, infectious virus particle. This process is catalyzed
by a viral protease (PR), which is itself embedded in one of
the polyproteins, and is one of the main targets of
antiretroviral drugs. We have developed the first full
reaction kinetics model that addresses the several layers of
complexity (multiple cleavage sites and substrates; multi-
ple enzyme forms; PR auto-processing) associated with the
proteolytic processing of HIV polyproteins. The model
allows us to identify the rate limiting step of virion
maturation and the parameters with the strongest effect
on maturation kinetics. We predict how changes in the
individual cleavage rates and the effects of drugs might
interact and possibly compensate each other, characterize
the detailed time course of the process, and explain why
the effectiveness of PR inhibitors rises very steeply at a
critical threshold concentration of the drugs. These new
insights promote our understanding of the viral life cycle
and may guide the future development of antiviral drugs.
Systems Modelling of HIV-1 Maturation
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Figure 2. The time course of simulated Gag and Gag-Pol processing. Initial concentrations of Gag and Gag-Pol were set to reflect the
quantities within a single virion; cleavage rates were parameterized according to in vitro estimates (Table 1). (A) Virus maturation time (VMT) as
defined by the molecular species known to govern virion maturation: Morphological maturation (indicated by dashed red line in all panels) is
triggered by the decay of the CA.SP1 fragment (blue line; threshold of trans-dominant inhibition of particle maturation indicated by dashed
horizontal line) and is not limited by the availability of liberated CA molecules (green line; threshold of one capsid unit corresponding to 1,500 CA
molecules per particle is indicated by solid horizontal line). (B) Generation of catalytically active intermediate dimeric forms containing PR. Full-length
Gag-Pol (red line) dimerizes rapidly and N-terminal auto-cleavage gives rise to enzymatically active intermediate dimeric forms (black, blue and green
lines). (C) Decay of Gag substrate (black line) and accumulation of final Gag cleavage products. (D) Accumulation of final Pol cleavage products. (E)
Enzyme concentrations and related metrics. The ratio PRdPR/Etot indicates the relative contribution of mature PR dimers to the proteolytic activity.
The ratio Etot/Stot of the total concentration of active enzyme forms and the total concentration of uncleaved cleavage sites stays below one
throughout the simulated time course, which justifies the use of Michaelis-Menten kinetics. Etot – total proteolytic activity; Stot – all uncleaved
cleavage sites; IEF – all active intermediate enzyme (PR) forms; RT: p51/p66 heterodimer. All other dimers are indicated in the form M1dM2, where M1,2
are the monomers.
doi:10.1371/journal.pcbi.1003103.g002
Systems Modelling of HIV-1 Maturation
PLOS Computational Biology | www.ploscompbiol.org 3 June 2013 | Volume 9 | Issue 6 | e1003103
Table 1. Parameters used for the simulation of the modela.
Parameter pH Value Unit References
kcat MA/CA 5.6 6.8 s
21 [17]
KM MA/CA 5.6 0.15 mM [17]
kcat CA/SP1 5.6 0.09 s
21 [13]
KM CA/SP1 5.6 0.01 mM [13]
kcat SP1/NC 5.6 3.7 s
21 [13]
KM SP1/NC 5.6 0.05 mM [13]
kcat NC/SP2 5.6 0.15 s
21 [16]
KM NC/SP2 5.6 0.17 mM [16]
kcat SP2/p6
gag 5.6 0.98 s21 [16]
KM SP2/p6
gag 5.6 1.2 mM [16]
kcat NC/TFP 5.0 1.9610
25 s21 [18]b
KM NC/TFP 5.0 0.05 mM [18]
b
kcat TFP/p6
pol 5.0 2.061024 s21 [18]b
KM TFP/p6
pol 5.0 0.05 mM [18]b
kcat p6
pol/PR 5.6 0.06 s21 [13]
KM p6
pol/PR 5.6 8.761023 mM [13]
kcat PR/p51 5.6 1.5 s
21 [13]
KM PR/p51 5.6 0.07 mM [13]
kcat p51/p15 5.6 0.4 s
21 [13]
KM p51/p15 5.6 0.04 mM [13]
kcat p15/IN 5.6 1.2 s
21 [13]
KM p15/IN 5.6 6.0610
23 mM [13]
kcat in PR 5.5 2.85 s
21 [15]c
KM in PR 5.5 0.215 mM [15]
c
kcat auto-cleavage 5.0/7.0 10
23 s21 [7,8]d
kass PRdPR 6.0 1.02610
3 mM21 s21 [19]
kdiss PRdPR 6.0 2.15610
23 s21 [19]
kass IEF
e 1.026102 mM21 s21 see belowf
kdiss IEF
e 2.1561023 s21 see belowf
kass Gag-Pol
g 1.026101 mM21 s21 see belowf
kdiss Gag-Pol
g 2.1561023 s21 see belowf
kass RT 14 mM
21 s21 [87]
kdiss RT 4.5610
23 s21 [87]
kass Darunavir 2.2610
3 mM21 s21 [43]
kdiss Darunavir 7.8610
27 s21 [43]
Initial concentration of Gag 3.619 mM Based on [22]
Initial concentration of Gag-Pol 0.1905 mM Based on [22]
aMany parameters are very sensitive to pH (for example Gag-Pol auto-cleavage [8,9], PR dimerization [14] and also the rates of heteromolecular cleavage). The pH within
virions is unclear; however, it may be assumed to be close to the optimum for PR activity (pH,5.5), we have therefore selected parameter estimates obtained at this pH
wherever available.
Initial concentrations were calculated based on data from [22] as follows. Radius of the virus: r = 63 nm = 6.361027 dm; number of Gag molecules: 2280; number of Gag-
Pol molecules: 120 (total Gag content: 2400). The volume of a virion V = (4p(r3))/3<1.05610218 dm3. Considering that 1 mol consists of 661023 molecules, (2280/
(661023) = 3.8610221 mol and 120/(661023) = 2610222 mol, then 3.8610221/1.05610218<3.61961023 mol/dm3 and 2610222/1.05610218 = 1.904761024 mol/dm3.
bNo direct estimates were available for these two cleavage sites. We used the median of the KM values estimated for the other canonical cleavage sites, and estimated
kcat from data presented in [18] (see supplementary Text S1).
cReflecting the fastest of three internal cleavage sites reported in [15].
dThe mean of the two reported values (1.3 and 0.761023) was used.
eIntermediate forms (dimers) with liberated N-termini but C-terminal flanking fragments still uncleaved in at least one of the monomers.
fNo empirical estimates were available for full length Gag-Pol and intermediate enzyme forms. Presumed decreased efficiency was implemented by decreasing the
association rate with one and two orders of magnitude, respectively, compared with the mature PR.
gIn addition to full-length Gag-Pol dimer, this category included the first intermediate product of auto-cleavage: MA.INTdPR.INT.
Abbreviations in the table: kcat – catalytic rate constant; KM – Michaelis constant; kass – association rate constant; kdiss – dissociation rate constant.
doi:10.1371/journal.pcbi.1003103.t001
Systems Modelling of HIV-1 Maturation
PLOS Computational Biology | www.ploscompbiol.org 4 June 2013 | Volume 9 | Issue 6 | e1003103
Figure 3. The processing of canonical cleavage sites in the simulations of Gag and Gag-Pol processing. (A) The fraction of a given
cleavage site that is yet uncleaved (the total concentration of all molecular species that contain the uncleaved site, divided by the initial
concentration of Gag or Gag-Pol, respectively). (B) The order of cleavage defined by the time points when a fixed threshold of processing (50% and
95%), indicated by horizontal lines, has been reached. (C) Schematic representation of the proposed order of processing events in HIV-1 Gag and
Gag-Pol, respectively. The size of the arrowheads indicates different rates of cleavage, with large arrowheads representing faster cleavage. The order
of processing for Gag is based on the times needed to attain 50% processing in the model, as in (B). Note that the sizes of arrowheads are not drawn
to scale.
doi:10.1371/journal.pcbi.1003103.g003
Figure 4. The effect of parameter variation on the virion maturation time (VMT). (A) The effect of varying each parameter individually
along a geometric series between 0.1 to 10 times its default value, while fixing all other parameters at their default values. Color symbols depict VMT
as a function of the parameters with the strongest effects (kcat of CA/SP1: red; rate constant of Gag-Pol auto-cleavage: blue; KM of NC/SP2: green; KM
(yellow) and kcat (brown) of p6
pol/PR; kd of Gag-Pol: purple); the effect of variation in all other parameters is illustrated by black symbols, which are
overlaid on the horizontal line positioned at default VMT, indicating no discernible effect. (B–C) Multivariate exploration of the parameter space. All
parameters were drawn randomly from lognormal distributions parameterized such that 95% of the values fell in the range of 0.1 to 10 times the
default value of the parameters, or 0.01 to 100 times the default for the parameters with no direct empirical estimates. Default parameter values are
indicated by solid vertical lines, the limits of the 95% range by dashed vertical lines. The catalytic rate constant of CA/SP1 cleavage (B) had a strong
impact on VMT; the rate constant of Gag-Pol auto-cleavage had very similar effect. None of the other parameters had any discernible effect on VMT:
(C) shows a representative example with VMT plotted against the catalytic rate constant of NC/SP2 cleavage. Results from 10,000 simulations are
shown; default VMT is indicated by solid horizontal line; parameters were plotted on a log scale in all three panels, with a dimension of s21 in B–C.
doi:10.1371/journal.pcbi.1003103.g004
Systems Modelling of HIV-1 Maturation
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panels of Figure 2) was estimated based on two criteria for
maturation: i) the presence of a sufficient number of liberated CA
molecules to form a mature conical capsid (one ‘‘capsid unit’’
corresponding to 1,500 CA monomers [31]), and ii) the
concentration of the late processing intermediate CA.SP1 falling
below a critical level. Processing at this site is required for mature
capsid formation [26,32–34]. A CA.SP1 concentration below 5%
of the total initial Gag content is needed to fully alleviate the trans-
dominant inhibition effect of this fragment on HIV-1 infectivity
[35], and we used this threshold as a criterion for attaining VMT.
The time needed for the assembly of the mature cone shaped
capsid was not considered in our definition of the VMT, which
implies that our estimates for VMT can be regarded as lower
bounds; however, assembly is likely to be fast compared with the
preceding steps of proteolytic processing (see Discussion). Using
the default parameters, our model predicted morphological
maturation to occur ,30 min after the start of the process, which
is thought to be initiated at the formation of the virion. While there
are no reliable data on the timing of virion maturation in vivo, the
fact that morphological maturation intermediates have not been
detected by electron microscopy indicates that the process is
comparatively fast. Our result is roughly consistent with the
current assumption that maturation occurs during or shortly after
budding [36], taken together with fluorescence imaging results
indicating that most HIV-1 virions are released from the cell
within 30 min after formation [37], apparently with a ,15 min
delay after the assembly of the Gag shell beneath the cell
membrane [23].
Total proteolytic activity (Figure 2E, green line) peaks around
39 min, and declines afterwards due to the internal cleavage of PR
monomers. Remarkably, the combined catalytic activity of all
intermediate enzyme forms exceeds that of the fully cleaved PR
homodimer until,35 min after the start of the process (Figure 2E,
blue line indicates the relative contribution of mature PR dimers to
the proteolytic activity). Up to the time of VMT (dashed red line),
intermediate enzyme forms are predicted to have catalyzed ,80%
of all cleavage reactions. Functional p66/p51 heterodimers of
reverse transcriptase (RT) also decline after a peak due to the
cleavage of the p66 subunit into p51 and p15 fragments; however,
this decay is arrested as PR activity is lost (this might occur even
faster in vivo: see Discussion). Finally, we have verified that the total
concentration of uncleaved cleavage sites greatly exceeds the total
concentration of active enzyme forms throughout the simulated
cleavage process (Figure 2E), which justifies the use of Michaelis-
Menten kinetics (assuming quasi steady state for the enzyme–
substrate complexes).
We also plot the time course of the overall processing of
individual cleavage sites in Figure 3A: the figure shows what
fraction of a given cleavage site is yet uncleaved (the total
concentration of all molecular species that contain the uncleaved
site, divided by the initial concentration). The order of cleavage
can be defined for fixed thresholds of processing: Figure 3B depicts
the order obtained for 50% and 95% processing; Figure 3C
presents a schematic representation of the order of cleavage events
based on 50% processivity. The order of events in our simulations
is roughly consistent with the order of events observed in vitro
[11,38], with two exceptions: the removal of the spacer peptide
from CA and the cleavage at the N-terminus of PR (p6pol/PR)
occur much faster in the simulations than in vitro. These
discrepancies arise from the relatively faster rates of cleavage
observed during the processing of oligopeptides, which were used
to parameterize the model. However, slowing down the processing
of the CA/SP1 site to reproduce the results of in vitro processing of
full-length Gag (as in [39]) results in VMT.2 hours (see
Discussion); we therefore used the parameter set derived from
oligopeptide cleavage (Table 1) in the subsequent analyses.
We thus conclude that our model is able to capture most known
characteristics of the cleavage process, and proceed to analyze
further properties of the system, for which little or no empirical
data exist yet.
Rates of Gag-Pol auto-cleavage and CA/SP1 cleavage set
the time scale for virion maturation
We next investigated the sensitivity of the maturation time to
the parameters of the model. These analyses provide insight into
the sensitivity of the results to the uncertainty of the parameters,
and also predict the response of the system to possible
interventions that affect individual steps of the process. We first
varied one parameter at a time (see Table 1 for the list of all 33
parameters) in the range of 0.1 to 10 times its default value, while
fixing all other parameters at their default values (Figure 4A).
Within the studied range, varying most parameters had hardly
any effect on the virus maturation time, with the exception of
two critical parameters, which emerged as dominant factors: the
rate constant of auto-cleavage by the full length Gag-Pol dimers,
and the catalytic rate constant of heteromolecular cleavage at the
CA/SP1 cleavage site. The dependence of VMT on both
dominant parameters was very similar: at the lower (slower) end
of the studied range, VMT is very sensitive to small changes in
these parameters, while at the higher (faster) end, further
increase in either rate constant yields diminishing reductions in
VMT. We also tested the effect of initial Gag content of the
virus. Since HIV-1 particles are not homogeneous, but have
been shown to vary with respect to diameter [40] and
completeness of the spherical Gag shell [22,25], this parameter
will vary among individual virions [41]. Varying initial condi-
tions from 1,600 to 3,500 molecules of total Gag content (while
keeping the Gag:Pol ratio of 20:1 constant) had negligible effect
on the time course of virion maturation (variation in VMT was
#1 second).
We next performed a multivariate exploration of the
parameter space. Parameters were drawn randomly from
Figure 5. Isoclines of virion maturation time (VMT). The isoclines
are drawn in the plane of the two rate parameters with the strongest
effect on VMT. Generic hyperbola-like functions of the form y = a+b/
(x2c)d could be fitted to the data. For VMT = 15 min: a = 1024,
b = 561024, c = 0.058, d = 0.69; for VMT = 30 min: a = 1024, b = 1024,
c = 0.027, d = 0.79; for VMT = 45 min: a = 961025, b = 261025, c = 0.017,
d = 0.93; dimensions for parameters a–c and for both axes of the figure
are s21. The perpendicular lines indicate the default values of both
parameters.
doi:10.1371/journal.pcbi.1003103.g005
Systems Modelling of HIV-1 Maturation
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lognormal distributions parameterized such that 95% of the
values fell in the range of 0.1 to 10 times the default value of the
parameters; for the few parameters with no direct empirical
estimates (the association and dissociation rate constants of full-
length Gag-Pol and partially cleaved PR enzyme forms, and the
KM values for the NC/TFP and TFP/p6
pol cleavage sites), we
allowed a range with plus/minus two orders of magnitude
around the default value. We performed 10,000 simulation runs
with independently generated random parameter sets, of which
8,937 achieved virion maturation by 120 min. Median VMT
(when censoring uncompleted runs at VMT=121 min) was
38.5 min (IQR: 22.4–66.6 min); the distribution of VMT was
non-normal (Kolmogorov-Smirnov test, p,10210; Figure S2).
Maturation was triggered by the loss of CA.SP1 inhibition in
7,141 (80%) of the cases where maturation occurred, and we
verified that the criterion for the Michaelis-Menten approxima-
tion (Stot.Etot) was fulfilled for nearly all (.99%) parameter sets.
The dominance of the catalytic rate constants of initial auto-
cleavage and CA/SP1 cleavage was confirmed in this analysis.
Of the 33 parameters, only four had a significant effect on VMT
(Spearman rank correlation test; p,0.0015 after Bonferroni
correction): this included both dominant rate constants, which
also displayed considerable correlation strength (Spearman’s
Rho of 20.58 and 20.45 for the CA/SP1 catalytic rate constant
and for the rate constant of Gag-Pol auto-cleavage, respectively).
The catalytic rate constant of the NC/SP2 cleavage and the
association rate constant of active (N-terminally free) partially
cleaved PR forms also affected the VMT according to this
analysis, but displayed only very weak correlation (Spearman’s
Rho around 20.03). Only the two dominant rate constants had
discernible impact on the distribution of plotted VMT values
(Figures 4B and C show the influence of a dominant rate
constant and of a representative ‘‘neutral’’ rate constant,
respectively).
We thus conclude that the time-limiting steps in virion
maturation (with current maturation criteria) are the initial auto-
cleavage of full-length Gag-Pol and the processing of the CA/SP1
cleavage site.
Compensation and interactions between the dominant
rate constants
Given the comparable magnitude of the impact of both
dominant parameters on VMT, any effect (mutation or drug)
involving one of the rate constants might be compensated by a
change in the other. We investigated the potential for such
compensation and for interactions (synergy [29,30] or antagonism)
between the rate constants. Figure 5 shows isoclines of VMT
(isoboles [30]) with the rate constant of Gag-Pol auto-cleavage
plotted against the CA/SP1 catalytic rate constant, with all other
parameters fixed at their defaults. All points of an isocline yielded a
fixed VMT (analogous to isoboles of combined drug doses of equal
activity [30]). The isoclines are hyperbola-like functions with both
vertical and horizontal asymptotes. This shape of the functions
implies that for any given VMT, there is a minimum value for
both parameters needed to achieve maturation within that given
time; the vertical asymptotes indicate the minimum rates for CA/
SP1 cleavage, the horizontal asymptotes indicate the minimal rate
constants for Gag-Pol auto-cleavage. Close to the asymptotes, the
corresponding slow rate becomes rate limiting, and very small
changes in the limiting rate constant can only be compensated by
large changes in the other parameter to maintain VMT. The
default (empirical) parameter setting happens to fall in the regime
where both parameters have comparable effect. This result
indicates that small decreases in either rate constant (by drug or
mutational effect) can be compensated by increases in the other
parameter; however, compensation becomes increasingly difficult
and eventually impossible as the affected rate parameter
approaches its critical (asymptotic) value.
Even where compensation is possible in terms of VMT, the time
course of Gag-Pol processing cannot be forced to return to the
original behaviour. When a change in one of the dominant
parameters is compensated by a change in the other to yield the
same VMT, the time course of the process remains different from
that obtained with the default parameters (Figure S3). ‘‘Complete’’
compensation of the time course would be possible only between
parameters that have very similar local sensitivity functions [42];
however, the local sensitivity functions of the two dominant rate
constants have different shapes (Figure S4). While some of the
other parameters have similar sensitivity functions (for example,
the sensitivity function of the Gag-Pol dissociation rate constant
has similar shape to that of the catalytic rate constant of Gag-Pol
auto-cleavage), the small magnitude of the effect of these on VMT
precludes any meaningful compensation of changes in either of the
dominant rate constants.
We next investigated the potential interactions between the
effects of the two dominant parameters when both are changed. In
particular, we tested whether combined changes are characterized
by either of two simple types of interaction: additive or
multiplicative effects. We used the following simple definitions
for the two types of interaction: using the notations VMTdef,
VMTA, VMTB and VMTAB to denote VMT obtained with the
default parameters, with one, the other, or both of the parameters
changed to a defined extent, we denote the absolute changes in
VMT due to changes in each parameter with d1=VMTA-VMTdef
and d2 =VMTB-VMTdef, and the fold changes with f1 =VMTA/
VMTdef and f2 =VMTB/VMTdef. The expected VMT when both
parameters are changed is then VMTAB=VMTdef+d1+d2 under
the additive model, and VMTAB=VMTdef*f1*f2 under the
multiplicative model. We use the comparison with these two
simple reference cases to illustrate the nature of the interaction
Figure 6. Accuracy of predicting combined parameter effects
on VMT assuming additive (A) and multiplicative (B) interac-
tion. Simulations were run with a geometric series of 20 values ranging
from 0.16 to 6.25 times the default for both parameters, and with all 400
combinations of the variants. Under the additive model, predictions of
combined effects were obtained by adding up absolute changes in VMT
observed when changing each of the parameters separately; predic-
tions under the multiplicative model were obtained by multiplying the
relative (fold change) individual effects. Deviations (in minutes) from
both predictions are plotted with color-coding; the dimensions of both
parameters were s21. The additive model performs better (smaller
deviation) when both parameters are increased or both are decreased;
the multiplicative model performs better when one parameter is
increased and the other decreased.
doi:10.1371/journal.pcbi.1003103.g006
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depending on the direction of intervention and possible compen-
satory effects. We varied both parameters along a geometric series
ranging from 0.16 to 6.25 times the default value, both separately
and in all possible combinations. We used the results from the
univariate series to predict the effect of combined changes
assuming both additive and multiplicative effects, and tested the
deviation of the simulations with combined changes from both
predictions (Figure 6). We found that the additive model fits
qualitatively better when both parameters are changed in the same
direction (both increased or both decreased; Figure 6A), while the
multiplicative model fits better when one parameter is increased
and the other decreased (Figure 6B). Two scenarios might be most
relevant biologically. First, compensatory mutations in one
parameter might restore VMT in the presence of drugs or
mutations that decrease the other parameter. In this case, one
parameter is decreased and the other increased, which results in
multiplicative interactions, consistent with the shape of the VMT
isoclines (Figure 5). This implies that a given fold increase in one of
the parameters can be compensated by a similar factor of decrease
in the other parameter to restore the default VMT. Second,
combinations of drugs might target both rates in concert, which
corresponds to a decrease in both parameters. For this scenario,
our results predict additive effects: the increase in VMT induced
by such a combination can be approximated by the sum of the
increases induced by monotherapy with the individual drugs.
Synergistic drug effects are not expected.
Figure 7. The effect of PR inhibitors on VMT. (A) The dependence of VMT on the concentration of PI that binds to mature PR (red symbols) and
on the concentration of a hypothetical PI that binds to full-length Gag-Pol dimers and inhibits auto-cleavage (blue symbols). The binding rate
constants of both PIs were parameterized with data estimated for the PR binding of darunavir. A hyperbola-like function of the form y = a+b/(c2x)d
could be fitted to the simulated VMT data, with a = 28.4 min, b = 8.75 min6mM, c =20.91 mM, d = 1.53 for the inhibitor of PR, and with a = 29.4 min,
b = 2.70 min6mM, c =20.97 mM, d = 1.51 for the inhibitor of auto-cleavage. The vertical line indicates the theoretical maximum concentration of PR
dimers at half of the initial concentration of Gag-Pol; the horizontal line indicates VMT in the absence of drug. (B) The effect of Gag-Pol content on
critical drug concentration. Red dots indicate the theoretical maximum concentration of functional PR enzymes (half of Pol) at varied initial Gag-Pol
content; black dots indicate the darunavir concentration required to delay virus maturation to VMT = 100 min in the model. (C) The dependence of
VMT on the dissociation rate constant kd of an inhibitor of PR (red) and of an inhibitor of Gag-Pol (blue). The inhibitor of auto-cleavage requires
greater binding affinity (lower log(kd)) to take effect. The vertical line indicates the estimated dissociation rate constant of darunavir. The horizontal
line indicates VMT in the absence of drug; drug concentration was set to the possible maximal enzyme concentration (half of initial Gag-Pol) at
0.095 mM. (D) Isoclines of VMT = 30, in the plane of darunavir concentration against fold increase in the two catalytic parameters with the strongest
effect on VMT. The same function as in (A) could be fitted with a = 0.57, b = 0.68 mM, c =21.36 mM, d = 1.10 for the catalytic rate constant of CA/SP1
cleavage, and with a = 0.70, b = 0.66 mM, c =21.18 mM, d = 0.94 for the catalytic rate constant of auto-cleavage. Vertical asymptotes (positioned by c
values) show the limits on the compensation of drug effect by increased catalytic rates. In all panels, parameters were set as in Table 1 unless
otherwise stated.
doi:10.1371/journal.pcbi.1003103.g007
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Protease inhibitor effect depends critically on inhibitor
concentration and binding affinity
The modelling framework also allowed us to characterize the
effect of PIs. As a test case, we selected darunavir, which is a potent
inhibitor of HIV-1 PR [43,44]. Figure 7A depicts the dependence
of virion maturation time on the concentration of darunavir (red
symbols) in the model. The response is very steep: VMT rises from
the default value to infinity within about an order of magnitude
range (,0.01–0.1 mM) of the drug concentration, which is
consistent with the steep dose response curves observed for PIs
[27]. However, the PI concentration, where maturation is lost in
the model is several orders of magnitude higher than the IC50
estimated for darunavir in infected cells in vitro [44], which calls for
an explanation (see below). The vertical asymptote where
maturation fails to occur is very close (at ,0.12 mM) to the
possible maximal concentration of PR dimers (at ,0.095 mM;
half of the initial Gag-Pol content), which implies that the majority
of the enzyme needs to be blocked by the highly efficient inhibitor,
if slower maturation still produces viable virions. This situation
corresponds to the ‘‘critical subset’’ model of drug action [45,46],
which applies when enzyme function is insensitive to the drug
concentration as long as a critical subset of enzyme molecules is
unbound, but is lost quickly in the regime where the increasing
drug concentration saturates the critical subset. Approximating the
critical subset with the concentration of PR dimers that remain
free in the presence of varied concentrations of the drug, the size of
the subset is predicted to be around 30 PR dimers, if
VMT=60 min is required for viability, or around 15 dimers, if
VMT.100 min is still tolerated (Figure S5). This result also
predicts that the critical drug concentration needed to block virion
maturation depends approximately linearly on the initial Gag-Pol
content, and mutations affecting Gag-Pol frameshift will therefore
have limited potential to compensate for the effect of PR inhibitors
[47]. Figure 7B confirms this prediction.
While the shape of the dose response curve was consistent with
the observations, there was a strong quantitative discrepancy
between the model predictions and the empirical dose response
observed in vitro. In the simulations, inhibition occurs where drug
concentration is in the range of the maximal PR concentration
(corresponding to half of the initial Pol content), which is in the
,0.1 mM range. In contrast, in vitro experiments estimated an
IC50 (half maximal inhibitory concentration) for darunavir in the
nanomolar range [44], which implies a four to five orders of
magnitude discrepancy between the estimates. The critical drug
concentration in the model depends only on the assumption that a
single drug molecule binds to and blocks a single PR dimer, and
on the estimated Pol content (,120 molecules) of a single virion.
For a nanomolar drug concentration to take effect, a single
molecule of drug should be able to block 104–105 PR dimers; in
fact, a nanomolar concentration would imply that the average
drug content of individual virions would be well below a single
drug molecule per virion (which would correspond to a
‘‘concentration’’ of ,1590 nM). That is, most virions would
contain no drug molecules, unless there is drug enrichment. This
result is independent of the details of the model, and the
discrepancy highlights an important additional process, which
has been overlooked previously. We propose that at low
(nanomolar) drug concentrations in the medium, the critical drug
concentration within the virion can be generated by diffusion and
(near) irreversible binding to PR, which together result in the
accumulation of drug from the surrounding medium to a form
bound to PR in the virion. Darunavir has relatively high
membrane permeability [48] and can even accumulate within
cells [49,50]. Assuming a drug concentration of 5 nM in the
medium, and free diffusion of darunavir to the nascent virion, we
calculate that the critical concentration (,0.1 mM; a 26104 fold
enrichment) required to block maturation can accumulate and
bind PR in as little as a few minutes (Materials and methods). The
rate limiting step is the association of the drug to PR, rather than
diffusion to the virion, and the concentration of unbound PR is
approximately halved per minute. Assuming that the critical subset
comprises 1/2, 1/4, 1/8 of the total PR pool, it would thus take
about 1, 2 or 3 minutes to accumulate the critical drug
concentration needed to inhibit maturation. This simplistic
calculation provides a lower boundary for the length of time
when Gag-Pol processing is susceptible to the drug effect [51].
Note, however, that the beginning of the susceptible period might
precede the budding of the virions, if the PR embedded in Gag-Pol
can already be targeted by the PI within the cell. More realistic
estimates for diffusion (that take into account possible barriers or
the extensive binding of darunavir to proteins [48]) might in the
future provide additional insight on the time window of
susceptibility to PIs during the viral life cycle.
The model can also be used to predict the dependence of the
drug effect on the binding affinity (parameterized by the dissociation
rate constant) of the drug (Figure 7C). We found that the response to
changes in the dissociation rate constant is similarly critical (steep) as
to the concentration of the drug. Furthermore, the critical binding
affinity required for the inhibition of maturation is several orders of
magnitude lower than the estimated binding affinity of darunavir
(and other potent drugs), which indicates that potent PIs operate
with a broad ‘‘safety margin’’. This is consistent with the
observation that for darunavir a nearly 1000-fold decrease in
binding affinity did not translate into a weaker antiviral activity [43],
and might contribute to the relatively high genetic barrier of the
drug. Implementing a hypothetical inhibitor that binds to full-length
Gag-Pol to block the initial auto-cleavage produced dose response
curves of very similar shapes; however, such inhibitors require much
stronger binding affinity (close to that of darunavir) to take effect on
VMT (Figure 7C: blue symbols), have weaker effect at the same
fixed affinity and concentration (Figure 7A: blue symbols), and
imply a smaller critical subset of unbound target molecules (Figure
S5). This difference probably arises because unbound Gag-Pol
molecules that undergo auto-cleavage generate active PR forms that
can no longer be targeted by an (exclusive) inhibitor of Gag-Pol; in
contrast, unbound PR remains a target for PIs until the cleavage of
its internal cleavage site, upon which protease activity is lost.
We also tested the potential of the catalytic rate constants to
compensate the effect of PIs (for example, by compensatory
mutations in the cleavage sites [52,53]). Figure 7D shows the
compensation plots (isoclines of VMT=30 min) of both dominant
catalytic rates against the concentration of darunavir, demonstrat-
ing a limited potential for compensation. The vertical asymptote of
the isocline for the CA/SP1 catalytic rate constant (at
1021.36<0.0436 mM) indicates that even an ‘‘infinite’’ catalytic
rate could only compensate a drug dose of about 36% of the
critical concentration (0.12 mM) that inhibits maturation com-
pletely, and in vivo drug levels with current dosing are likely to
exceed the critical concentration considerably. The prediction of
limited compensatory potential is in apparent contradiction with
some empirical data that show clear compensation by substrate
mutations in tissue culture and selection of such mutations in vivo
[52,53]); see the Discussion for a possible explanation.
Initial inoculum of mature PR cannot substantially
accelerate virion maturation
Finally, we investigated whether a small initial inoculum of
mature PR would be able to accelerate virion maturation. Such an
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inoculum could potentially be derived either from the infecting
virion or from Gag-Pol processing within the cell before virion
assembly and budding. Figure S6 illustrates that a small initial
inoculum has only a modest effect on the time to virion
maturation; for example the addition of PR corresponding to
10% of Gag-Pol content reduces VMT from 30 min to about
25 min. A greater initial concentration of PR is unlikely at the
beginning of the maturation process, given that premature
proteolysis prior to confining the components in an assembling
virion abolishes particle formation [54], which suggests that the
bulk of proteolysis of virion associated proteins only occurs in the
assembled virion (at or shortly after the time of budding). We
therefore conclude that an initial inoculum of PR is unlikely to
contribute substantially to proteolytic activity during maturation.
The time scale of virion maturation therefore depends on Gag-Pol
auto-cleavage within the virion, as has been assumed in our model.
This result is also consistent with the observation that N-terminal
cleavage follows first-order kinetics in protein concentration [8,9],
which implies that the dominant mechanism is intramolecular,
rather than heteromolecular cleavage.
Discussion
Our simulations of Gag-Pol processing are consistent with most
of the known features of Gag-Pol processing (approximate time
scale, order of release of final products), and can offer important
insights into further details of the process that are not amenable to
empirical study. In particular, we predicted the rate limiting steps
in the maturation process, and our results suggest that the auto-
cleavage of Gag-Pol dimers and the PR catalyzed cleavage at the
CA/SP1 site are the most promising candidates for future drugs
that would target individual steps of the proteolytic process.
Importantly, bevirimat, the first clinically tested HIV-1 inhibitor
that targets an individual cleavage site, as well as the chemically
unrelated inhibitory compound PF-46396, affect cleavage at the
CA/SP1 boundary [4,5]. Unfortunately, drug combinations (or
mutations) that inhibit or impair both dominant steps are not
predicted to have a synergistic effect. Our model also provides a
simple mechanistic explanation for the steep dose response curves
associated with PIs [27], and highlights the importance of diffusion
mediated drug accumulation in the virions (or in the infected cells
before virion budding), which calls for further analyses. We
demonstrated that the maturation process is robust with respect to
variation in Gag content, and therefore also to stochastic biological
variations in virion assembly, and showed that a small initial
inoculum of mature PR is unable to ‘‘kick-start’’ the process. The
model predicted that intermediate PR forms (with uncleaved C
termini) may contribute substantially to proteolytic processing (this
result clearly depends on the assumption that such intermediate
forms have efficient catalytic activity [8,55]). We also found that
the self-cleavage of PR results in a loss of PR activity after the
completion of maturation, which might be an evolutionary
adaptation to avoid the loss of RT activity due to the cleavage
of all p66 monomers and the possible loss of CA monomers due to
cleavage of CA at non-canonical internal cleavage sites [17].
Finally, we were also able to predict the compensatory potential
between drugs or mutations that affect the rate limiting steps or
block PR activity. The compensatory potential of mutations
affecting Gag-Pol frameshift [47] could also be investigated with
the models.
While our ‘‘full model’’ of Gag-Pol processing provides valuable
insights, this simplistic modelling approach clearly has a number of
limitations. The use of mass action reaction kinetics assumes a
well-mixed homogeneous system with concentrations described on
a continuous scale, while both immature and mature virions have
organized spatial structure [21,40,56,57] and the number of
enzyme and substrate molecules within a virion has a limited
discrete scale of the order of hundreds and thousands, respectively
[22,31]. These constraints are likely to affect HIV-1 proteolytic
processing and limit the validity of our model predictions [58]. To
mitigate these limitations, the low number of interacting molecules
could be addressed relatively simply by discrete stochastic
modelling [59], while the introduction of explicit space would
require a major re-structuring of the model, and might be a
promising direction for further study.
Furthermore, the criteria that we used for maturation may have
been incomplete. Our criteria for VMT involved the steps of
proteolytic processing required for the morphological maturation
of the capsid [25,31,35], but not the time needed for the assembly
of the mature capsid. However, two observations indicate that
assembly of the mature cone probably does not take very long: EM
analyses have never revealed distinct maturation intermediates
and in vitro assembly of CA seems to be very rapid following
induction by high salt [60] (although assembly must be induced by
a different trigger in vivo). Given these caveats, our definition of
VMT based on processing criteria can be regarded as a lower
bound but is likely to be a good approximation of the time to
morphological maturation. However, there are probably other
criteria for the viability (infectivity) of virions: each of the enzymes
and structural proteins of the virus probably has a critical required
count. Should quantitative data on other criteria be identified in
the future, the model can easily be extended to accommodate the
further requirements. We note also that the current limited
maturation criteria are likely to introduce a bias on the set of
parameters that can potentially influence VMT: the MA/CA,
CA/SP1 and SP1/NC cleavage sites have direct effect on the
molecular species that appear in the maturation criteria (of these,
the processing of the MA/CA and SP1/NC cleavage sites occurs
much faster than that of the CA/SP1 site, with kcat/KM ratios of
45 and 74 vs. 9, which explains why only the latter has strong rate
limiting effect), while Gag-Pol auto-cleavage is strictly needed to
initiate processing, its rate therefore has a ubiquitous effect on the
time course of the process. However, even with the current
criteria, other rates (cleavage sites) could have strong indirect
effects by competing for the available enzymes. The identity of the
dominant rates is therefore not hard-wired in the structure of the
model, but depends on the relative magnitude of all kinetic rates.
For example, re-parameterizing the model with cleavage rates
estimated with full-length Gag changes also the identity of rate
limiting steps (see below).
To be able to use a consistent set of parameters, we had to rely
on estimates obtained from the in vitro cleavage of oligopeptides
containing individual cleavage sites in solution. However, flanking
regions around the cleavage sites [20] and the extended context of
variations in both the substrates and the enzyme [58] are likely to
have an effect on the rates of cleavage by influencing the access of
PR to the sites. In addition, the incorporation of Gag and Gag-Pol
molecules in the strictly organized lattice architecture and the
limited movement of molecules within the confined space of the
virion are also likely to influence the effective cleavage rates. These
effects may be particularly apparent regarding the removal of the
spacer peptides by cleavage at the CA/SP1 and NC/SP2
processing site, respectively. Based on all available virological
data, SP cleavage is considered to be a late event occurring after all
other cleavages within Gag, which is not reflected in our
simulations that were parameterized with peptide kinetic data
(Figure 3B). There is indeed evidence that the CA/SP1 sites and
NC/SP2 sites are sensitive to the lattice and RNA context. For
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example, the presence of uncleaved MA upstream [26], uncleaved
NC downstream [11] or a proportion of uncleaved CA-SP1-NC
molecules in the particle [35] reduces cleavage at the CA/SP1 site.
Furthermore, exposure of the NC/SP2 site has been shown to be
sensitive to the spatial organization of the RNA strands within the
virion [61]. Such indirect effects might be responsible for the
potency of the NC/SP2 cleavage site to affect the time scale of
Gag processing and to compensate for inhibition by PIs [52,53]),
even though such an effect was not predicted in our simulations.
Cleavage at this site was found to be much slower in the context of
full-length Gag compared with that of short oligopeptides [11],
which might increase the impact of this cleavage site on the time
scale of virion maturation.
For Gag, quantitative empirical data are also available for the
cleavage of the full polyprotein in vitro [11], and the relative rates
estimated for some of the cleavage sites are different from those
obtained in the context of oligopeptides, which might reflect the
effect of flanking groups. We tested how an alternative set of
cleavage rates in Gag, fitted to the empirical data on full-length
Gag cleavage (adopted from [39]) affects the results of our model.
The most important difference in the parameters is that CA/SP1
cleavage was much slower (kcat decreased, KM increased) compared
with the estimates obtained with oligopeptides. As a result, virion
maturation occurred much later, around ,144 min (Figure S7),
which is inconsistent with the fact that many released virions
captured close to the cell by electron microscopy are mature and
no morphological maturation intermediates are observed. Thus,
although the true in vivo relative rates might be better approx-
imated in the experiments that worked with full-length Gag
instead of oligopeptides, the absolute rates of cleavage are likely to
be much faster in vivo in the maturing virions. Furthermore, even
full-length Gag in vitro is unlikely to reflect the spatial effects
occurring in whole virions. However, the testing of this alternative
parameter set yielded an important insight: the sensitivity of VMT
to individual parameters also changes (Figure S8) compared with
the default settings; a greater number of parameters have
discernible effect on VMT with this parameter setting. This
indicates that while our predictions on the identity of rate limiting
steps are very robust as long as the dominant rate constants remain
relatively close to their original values, large changes in these
parameters (in this case in both CA/SP1 kinetic rate constants)
may re-define the rate limiting steps of the process. In particular, it
remains to be seen how well the currently used parameter
estimates that were obtained with oligopeptide substrates reflect
the real relative rates of cleavage in vivo: if future empirical work
calls for major changes in the parameters, the simulation analyses
should be repeated to accommodate the effect of the new
estimates.
Functional p66/p51 heterodimers of reverse transcriptase (RT)
decline to a relatively low level due to the cleavage of the p66
subunit into p51 and p15 fragments in the model. However,
immunoblot analyses indicate that p66 and p51 persist in mature
virions at approximately equal concentrations [62,63], which
suggests that some mechanism might protect RT from proteolysis
in vivo. For example, the p51/p15 cleavage site might be cleaved
preferentially in the context of p66 homodimers [38,64], with
greatly reduced cleavage both in monomers and in the functional
heterodimer.
Finally, in all analyses we could only investigate VMT (the time
to virion maturation) as a surrogate metric for the success of virion
maturation. VMT predicted with the empirical set of kinetic
parameters was consistent with current models of release and
maturation [23,36,37], although some studies have estimated a
longer time scale of several hours [65], while another retrovirus
(Moloney Murine Leukemia Virus) seems to achieve partial
maturation in as little as 5 minutes after release [66]. However, we
have no direct data on how VMT translates to infectivity. As a
rough approximation, maturation should be completed within the
mean lifespan of virions, which is around ,1 h in the blood
plasma [67], and a few hours [68] or possibly even shorter [69] in
the lymphoid tissues. Furthermore, cell-to-cell transmission (which
plays a major role in HIV infection [70]) would also require rapid
maturation after release; indeed, mature particles have been
clearly observed in the virological synapse [71], although another
study claimed that maturation only occurs upon endocytic uptake
of the virus across the synapse [65]. However, further studies will
be needed to better characterize VMT and its influence on
replicative capacity of the viruses. In terms of the predicted drug
effects, our results are likely to be robust due to the steep response
curves: in the regime of the critical concentration and efficacy of
drugs, VMT rises very sharply towards infinity (Figure 7), which
firmly nails down the critical threshold required to block virus
maturation effectively.
To our knowledge, our model is the first attempt to build and
analyze a full model of proteolytic Gag-Pol processing in maturing
HIV-1. Previous mathematical analyses have been restricted to
approximating drug effect on series of subsequent cleavage
reactions [72], without tracking individual substrates and products,
while our previous analysis addressed the in vitro processing of Gag
only [39]. The model developed here represents a major extension
by taking into account all processing events for Gag and Gag-Pol,
initial auto-cleavage and explicit enzyme dynamics. While subject
to a number of limitations in its current form, this simulation
framework provides a flexible platform to incorporate emerging
empirical data in the future, including additional criteria for virus
maturation or infectivity, measurements on the time course of
proteolytic processing in whole virions (not available currently, but
possibly amenable to emerging new technology), or more accurate
data on the virion maturation time. Even current technology
would allow the estimation of all kinetic rate constants (as in
Table 1) for mutant PR forms, which could be used to generate
detailed predictions on the influence of the mutations on the
proteolytic process. The estimation of kinetic rates for combina-
tions of PR forms, cleavage site variants and defined drug
conditions could be used to characterize, and predict, complex
evolutionary pathways under drug pressure. Quantitative data on
the relationship between viral fitness and concentrations of
functional RT or integrase could be used to predict the
interactions of these drug classes with PR inhibitors [73] or PR
mutations that impair the processing of these enzymes. Finally, the
framework will be applicable to other viruses that rely on
proteolytic processing of virion components, given that sufficient
data on the respective cleavage rates are collected (for example,
some kinetic data are available for the retroviruses feline
immunodeficiency virus [74], Rous sarcoma virus [75] and
murine leukaemia virus [76]). The publication of our full
computer code under open access as a supplement to this paper
will further facilitate the extension and broad application of this
modelling framework in the future.
Materials and Methods
Notation of molecular species
Fully cleaved HIV-1 proteins and peptides are denoted by their
standard abbreviations and nomenclature (see legend to Figure 1).
Partially processed intermediates are denoted by concatenating the
notations for the starting and the end fragment, for example, the
intermediate species spanning CA-SP1-NC is denoted by CA.NC,
Systems Modelling of HIV-1 Maturation
PLOS Computational Biology | www.ploscompbiol.org 11 June 2013 | Volume 9 | Issue 6 | e1003103
the species spanning NC-TFP-p6pol-PR-p51 is denoted by NC.p51,
etc. Dimers are denoted in the formM1dM2, whereM1,2 denote the
monomers; for example, PRdPR denotes the mature homodimer of
fully liberated protease, MA.INdPR.IN denotes the initial product
of the first step of Gag-Pol autocleavage.
Model structure
Gag-Pol processing by the HIV-1 PR is a specific case of
catalyzed competitive heteropolymer cleavage, for which we have
developed a generic modelling framework in terms of Michaelis-
Menten reaction kinetics under the quasi-steady-state (QSS)
approximation [39]. In an abstract notation, let Si denote the i
th
monomer of the heteropolymer; Si,j a fragment spanning
monomers i to j; and let the cleavage site h refer to the site C
terminal to the hth monomer. Free protease can bind reversibly to
any of the cleavage sites of a fragment such that i#h,j, and let Shi,j
refer to an enzyme-substrate complex in which the enzyme is
bound to cleavage site h within the fragment Si,j. Assuming
Michaelis-Menten kinetics, the steady-state concentration of
enzyme-substrate complexes can be written as S^hi,j~(Si,j  Efree)=
K
i,j,h
M , where Efree denotes the concentration of free enzyme and
K
i,j,h
M denotes the Michaelis-Menten constant of the cleavage of
fragment Si,j at cleavage site h. Using Etot = Efree+Ebound and
summing over all distinct enzyme-substrate complexes we obtain:
S^hi:j~(Si,j  Etot)=(Ki,j,hM  (1zR)), where R~
Pn{1
i~1
Pn
j~iz1
Pj{1
h~i
(Si,j=
K
i,j,h
M ) with n denoting the length (number of distinct monomers) of
the heteropolymer [39]. The rate of change in the concentration of
Si,j can then be calculated as shown in Figure 8 (with k
i,j,h
cat denoting
the catalytic rate constant of the cleavage of fragment Si,j at
cleavage site h). For example, the fragment CA.NC can be
produced by the cleavage of MA.NC at the MA/CA cleavage site
or by the cleavage of any CA.X fragment with X being a
monomer downstream of NC at the NC/TFP cleavage site; and
can be lost by internal cleavage at the CA/SP1 or the SP1/NC
cleavage sites.
Proteolytic processing is initiated by the auto-cleavage of the
full-length Gag-Pol dimer, which liberates the N-termini of both
embedded PR domains in two steps [9,28,77–79]. PR activity is
hampered primarily by the N-terminal flanking fragments of Gag-
Pol [9,55,77,80], and PR intermediates extended at the C
terminus have been shown to have catalytic activity comparable
to that of the mature enzyme [8,55]. We therefore assumed that
dimers of partially cleaved PR forms that have free N termini but
uncleaved flanking groups at their C terminus already possess
catalytic activity. For simplicity, we assumed that all active enzyme
dimers have the same catalytic activity, and C terminal groups
affect the efficiency of dimerization [81], rather than the rates of
catalysis.
The model also tracked the formation and breakup of homo-
and heterodimers of full-length Gag-Pol, intermediate and mature
PR forms, and of p51/p66 heterodimers of the reverse transcrip-
tase (RT). Because the quasi steady state of competing dimeriza-
tion reactions cannot be computed in a closed form, we
implemented a ‘‘hybrid’’ time scale in which enzyme-substrate
complexes were kept in QSS within one time step, even though
enzyme dimers were not. At the beginning of each time step, we
summed up the level of enzymatic activity (total concentration of
active enzyme dimers, Etot), and calculated the QSS for the
enzyme-substrate complexes. The QSS concentrations of the
complexes determined the rates of the net cleavage reactions
within a time step. Enzyme dimers were allowed to form and
dissociate within one time step, but the level of enzyme activity was
only updated at the beginning of the next time step. Thus the
iterative steps of our model were the following: 1) Sum up all active
(intermediate and mature) enzyme dimers to calculate Etot; 2)
calculate the QSS of enzyme-substrate complexes; 3) numerical
integration of reactions involving the association and dissociation
of enzyme dimers, the auto-cleavage reaction and the net cleavage
reactions.
Because cleavage rates are typically estimated in the context of
oligopeptides, the effect of flanking groups on cleavage could not
be taken into account, that is, the same cleavage site was always
cleaved with the same rate, irrespective of the substrate it was
Figure 8. The rate of change in the concentration of a given fragment Si,j . Assuming quasi steady state for the enzyme-substrate complexes,
Shi,j , the rate of change consists of loss by cleavage at any of the internal cleavage sites, and production by ‘‘trimming’’ longer fragments that have an
uncleaved site at either terminus.
doi:10.1371/journal.pcbi.1003103.g008
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located in. We thus set K
i,j,h
M ~K
h
M and k
i,j,h
cat ~k
h
cat for all (i,j). All
parameters are listed in Table 1.
For simplicity, dimers were assumed to be resistant to cleavage.
In addition to the 11 canonical cleavage sites, we also implement-
ed a non-canonical cleavage site within the mature PR monomer
[15], which might be important for the auto-inactivation of
proteolytic activity. Finally, we implemented two types of
inhibitors: ‘‘classic’’ PIs that bind to active (intermediate and
mature) PR dimers, and another hypothetical type that binds to
dimers of full length Gag-Pol and blocks auto-cleavage (for
simplicity, cross-inhibition of both types of dimers was not
allowed).
Implementation
The model was implemented in the C programming language,
using an adaptive fifth order Cash-Krap Runge-Kutta algorithm
for numerical integration of ordinary differential equations [82].
The full computer code of the simulations is available in the
supplement Text S2. For the local sensitivity analyses, to be able to
use the DASAC package [83], we have re-implemented the model
in the Fortran programming language. We have verified that the
two implementations yield consistent results.
Global sensitivity analysis
The following 33 parameters were varied either individually or
in combination: kcat and KM values for the 11 canonical cleavage
sites and for the non-canonical internal cleavage site within PR;
the rate of Gag-Pol auto-cleavage; the association and dissociation
rates for the three classes of PR containing enzyme forms: mature
PR, intermediate enzyme forms with cleaved N terminus, and full-
length and intermediate forms with N terminal flanking groups;
finally, the association and dissociation rates of RT heterodimers.
Local sensitivity analysis
Local sensitivity analyses demonstrate how a small change in a
particular parameter (from its default value) affects the time course
of the concentrations during the simulations. The sensitivity of
each variable (molecular species) with respect to each parameter is
obtained as a function of time (along the time course of the
simulated proteolytic process). We used half-normalized sensitivity
functions that express the change in substrate concentrations as a
function of relative change in a parameter (how much, in absolute
units, does the concentration change, if we change the parameter
by 1%). Local sensitivity analyses were performed with the help of
the DASAC package [83] using the Fortran implementation of the
model.
Calculating the accumulation of darunavir by diffusion
Our simple calculation was based on diffusion from bulk
medium to the surface of a sphere, assuming steady-state
concentration gradient around the sphere and immediate uptake
at the surface. Under these assumptions, total flux to the sphere
(rate of accumulation) can be calculated as: Q~4PDrCo, where D
is the diffusion coefficient, r is the radius of the sphere and C0 is the
concentration in the bulk medium (at ‘‘infinite’’ distance from the
sphere) [84]. The diffusion coefficient can be estimated by the
Wilke-Chang method [85] as D~7:4|10{8 WMbð Þ1=2T

gbV
0:6
a ,
where W is a dimensionless association factor of the solvent (equal
to 2.6 for water), Mb is the molecular weight of the solvent
(18.02 Da for water), T is the temperature in kelvins, gb is the
viscosity of the solvent (0.862 cP for water at 300 K) and Va is the
molar volume of the solute (408.4 cm3 for darunavir), which yields
a diffusion coefficient of D=4.7861026 cm2 s21 for darunavir at
T= 300 K in water. Given the estimated radius of a virion at
r=63 nm [22] and using a nanomolar concentration of C0=5 nM
for the bulk medium, the rate of accumulation of darunavir in the
virion is estimated as Q<2610221 mol/s. Considering an initial
Gag-Pol content of 120 molecules per virion [22], the maximum
amount of PR dimers is 60, or Emax=10
222 mol per virion. The
time needed to accumulate an equal amount of drug molecules
can then be calculated as ta = Emax/Q=0.05 s. Assuming that this
idealized diffusion process continuously replenishes the drug
molecules that bind PR dimers within the virion, the drug
concentration within the virion can be approximated with that in
the bulk medium, and the binding kinetics of PR dimers by the
drug can be characterized by the equation dE/dt = kass*C0*E,
where E denotes the concentration of unbound PR dimers and kass
is the association rate of the drug. The time until a fraction f of all
dimers remains unbound can then be calculated as 2ln(f)/kass*C0.
Using the association rate of darunavir (Table 1) and C0=5 nM,
the concentration of unbound enzyme is approximately halved per
minute (t1/2<63s). Given that the dissociation rate of darunavir is
,1026/s (Table 1), the dissociation of drug-enzyme complexes
can be neglected on the time scale of minutes.
Statistics and function fitting
Statistical tests were performed using the R statistical environ-
ment [86]. Mathematical formulae were fitted to data points using
the nls() function of R.
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Figure S1 The time course of the major intermediates of
simulated Gag (A) and Gag-Pol (B) processing.
(PDF)
Figure S2 The distribution of virion maturation times from
10,000 simulations with random parameter sets.
(PDF)
Figure S3 Compensation of virion maturation time (VMT) with
different time courses of reaction products.
(PDF)
Figure S4 Half-normalized local sensitivity functions of the
concentration of CA.SP1 with respect to selected parameters.
(PDF)
Figure S5 The size of the critical subset of PR or Gag-Pol
dimers as a function of VMT required for viability. Simulations
were run with different concentrations of two types of inhibitors
binding either to mature PR (red symbols) or to full-length Gag-
Pol dimers (blue symbols). The binding rate constants of both PIs
were parameterized with data estimated for the PR binding of
darunavir. The concentration of unbound enzyme was approxi-
mated by the total concentration of dimers minus the drug
concentration; the axis to the right shows the corresponding
numbers of dimers per virion. The amount of unbound enzyme
characterizes the ‘‘critical subset’’ required to complete proteolytic
processing within a given time (VMT). For example, the size of the
subset is predicted to be around 30 PR dimers, if VMT=60 min is
required for viability, or around 15 dimers, if VMT.100 min is
still tolerated. In the case of an inhibitor that binds Gag-Pol
dimers, the critical subset of unbound target molecules was smaller
than for the inhibitor of mature PR dimers at the same required
VMT.
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Figure S6 Adding an initial inoculum of mature protease results
in modest decrease in VMT.
(PDF)
Figure S7 The time course of simulated Gag and Gag-Pol
processing, using kinetic rate constants estimated based on full-
length Gag cleavage. (A) Virus maturation time (VMT) (dashed
red line in all panels) is still triggered by the decay of the CA.SP1
fragment (blue line; threshold of trans-dominant inhibition of
particle maturation indicated by dashed horizontal line) and is not
limited by the availability of liberated CA molecules (green line;
threshold of one capsid unit corresponding to 1,500 CA molecules
per particle is indicated by solid horizontal line), but occurs much
later than with the default parameters. (B) Generation of
catalytically active intermediate dimeric forms containing PR.
(C) Decay of Gag substrate (black line) and accumulation of final
Gag cleavage products. (D) Accumulation of final Pol cleavage
products. (E) Enzyme concentrations and related metrics. The
ratio PRdPR/Etot indicates the relative contribution of mature PR
dimers to the proteolytic activity. The ratio Etot/Stot of the total
concentration of active enzyme forms and the total concentration
of uncleaved cleavage sites stays below one throughout the
simulated time course, which justifies the use of Michaelis-Menten
kinetics. Etot – total proteolytic activity; Stot – all uncleaved
cleavage sites; IEF – all active intermediate enzyme (PR) forms;
RT: p51/p66 heterodimer. All other dimers are indicated in the
form M1dM2, where M1,2 are the monomers. Initial concentra-
tions of Gag and Gag-Pol were set to reflect the quantities within a
single virion; cleavage rates in Gag were parameterized as in [39];
all other parameters were set as in Table 1.
(PDF)
Figure S8 The effect of single parameter variation on VMT
using an alternative set of kinetic rate constants.
(PDF)
Text S1 Estimation of catalytic rate constants.
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Text S2 Computer code of simulations.
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